NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia. The company is also developing NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a clinical stage indoleamine-2, 3-dioxygenase pathway inhibitor. In addition, it is developing tergenpumatucel-L and dorgenmeltucel-L that are in Phase II clinical trials for treating patients with advanced lung cancer and melanoma; and CRLX101 and CRLX301, which are in early clinical development to treat patients with advanced solid malignancies. The company has strategic collaboration agreement with AstraZeneca to evaluate the combination of indoximod and durvalumab, an anti-PD-L1 monoclonal antibody for treating patients with metastatic pancreatic cancer; Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe and Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NLNK
CUSIP65151110
Phone515-296-5555
Debt
Debt-to-Equity RatioN/A
Current Ratio8.01
Quick Ratio8.01
Price-To-Earnings
Trailing P/E Ratio-2.24
Forward P/E Ratio-2.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$28.71 million
Price / Sales6.76
Cash FlowN/A
Price / CashN/A
Book Value$4.09 per share
Price / Book1.28
Profitability
EPS (Most Recent Fiscal Year)($2.30)
Net Income$-71,950,000.00
Net Margins-193.44%
Return on Equity-55.64%
Return on Assets-44.63%
Miscellaneous
Employees76
Outstanding Shares37,170,000
NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions
What is NewLink Genetics' stock symbol?
NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."
How were NewLink Genetics' earnings last quarter?
NewLink Genetics Corp (NASDAQ:NLNK) issued its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.55) by $0.06. The biotechnology company earned $9.90 million during the quarter, compared to analysts' expectations of $5.78 million. NewLink Genetics had a negative net margin of 193.44% and a negative return on equity of 55.64%. View NewLink Genetics' Earnings History.
When is NewLink Genetics' next earnings date?
What price target have analysts set for NLNK?
6 brokers have issued 12-month price targets for NewLink Genetics' stock. Their predictions range from $5.00 to $25.00. On average, they expect NewLink Genetics' share price to reach $11.3333 in the next twelve months. View Analyst Ratings for NewLink Genetics.
What are Wall Street analysts saying about NewLink Genetics stock?
Here are some recent quotes from research analysts about NewLink Genetics stock:
- 1. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (6/7/2018)
- 2. Cantor Fitzgerald analysts commented, "Data from a Phase I study of indoximod in diffuse intrinsic pontine glioma (DIPG) presented at AACR were positive, in our view, but given the recent failure of Incyte’s (INCY, NC) epacadostat, we do not believe that is likely to sway investors at this point." (4/16/2018)
Who are some of NewLink Genetics' key competitors?
Some companies that are related to NewLink Genetics include ANI Pharmaceuticals Inc Common Stock (ANIP), Amphastar Pharmaceuticals (AMPH), Abeona Therapeutics (ABEO), Inflarx (IFRX), Urogen Pharma (URGN), Vectura Group (VEGPF), Geron (GERN), Homology Medicines (FIXX), Odonate Therapeutics (ODT), Arcus Biosciences (RCUS), Adamas Pharmaceuticals (ADMS), GlycoMimetics (GLYC), Dicerna Pharmaceuticals (DRNA), Evolus (EOLS) and Viking Therapeutics (VKTX).
Who are NewLink Genetics' key executives?
NewLink Genetics' management team includes the folowing people:
- Mr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 59)
- Mr. Nicholas N. Vahanian M.D., Co-Founder, Pres, Chief Medical Officer & Director (leave of absence) (Age 51)
- Mr. John B. Henneman III, CFO & Sec. (Age 56)
- Mr. Carl W. Langren, VP of Fin. & Principal Accounting Officer (Age 63)
- Mr. Brian Wiley, Chief Commercial Officer (Age 50)
Has NewLink Genetics been receiving favorable news coverage?
News articles about NLNK stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. NewLink Genetics earned a news impact score of 0.18 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 46.76 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are NewLink Genetics' major shareholders?
NewLink Genetics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include 1GLOBE CAPITAL LLC Total Shares: 2,589,513 (6.97%), First Eagle Investment Management LLC (6.31%), BlackRock Inc. (6.08%), Redmile Group LLC (5.53%), JPMorgan Chase & Co. (1.33%) and Wells Fargo & Company MN (1.11%). Company insiders that own NewLink Genetics stock include Carl W Langren and Stine Seed Farm, Inc. View Institutional Ownership Trends for NewLink Genetics.
Which institutional investors are selling NewLink Genetics stock?
Which institutional investors are buying NewLink Genetics stock?
NLNK stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Arnhold LLC, Alambic Investment Management L.P., Wells Fargo & Company MN and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for NewLink Genetics.
How do I buy shares of NewLink Genetics?
Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NewLink Genetics' stock price today?
One share of NLNK stock can currently be purchased for approximately $5.22.
How big of a company is NewLink Genetics?
NewLink Genetics has a market capitalization of $198.83 million and generates $28.71 million in revenue each year. The biotechnology company earns $-71,950,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis. NewLink Genetics employs 76 workers across the globe.
How can I contact NewLink Genetics?
NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE SUITE 5100, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]
MarketBeat Community Rating for NewLink Genetics (NLNK)
MarketBeat's community ratings are surveys of what our community members think about NewLink Genetics and other stocks. Vote "Outperform" if you believe NLNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NLNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
